Target: Alphatec Holdings, Inc. (Nasdaq: ATEC) Audit domain: Political Research date: 26 October 2026 Evidence period: Historical corporate disclosures through October 2026
Corporate Communications & Public Stance
Corporate identity and communications.
Alphatec Holdings, Inc. is a Delaware-incorporated medical technology company headquartered in Carlsbad, California, identified in SEC records under CIK 0001350653 and operating in the surgical and medical instruments sector.1
The company’s official investor-relations profile describes its business as developing technologies and surgical approaches for treating spinal conditions, incorporating its Alpha InformatiX platform.2
In January 2026, Alphatec announced preliminary 2025 consolidated revenue of approximately $764 million and a 2026 revenue outlook of $890 million; the announcement described its activities as spinal surgery innovation and commercial development.3
In August 2026, the company reported second-quarter revenue of approximately $214 million, attributed principally to the performance of its surgical business.4
Israel-Palestine statements.
No public evidence identified of an official Alphatec Holdings statement expressly supporting either party in the Israel-Palestine conflict, endorsing military action, addressing Palestinian civilian casualties, or advocating a specific diplomatic settlement.
EOS imaging, before its acquisition by Alphatec, publicly announced its first Israeli medical-imaging-system sale on 5 April 2017 [pre-2020], identifying Tel Aviv Sourasky Medical Center as the customer and presenting the transaction as an expansion of its medical-imaging business.5
The historical announcement remains publicly retrievable from EOS imaging’s own website in October 2026, while the current EOS corporate website identifies the business as part of the ATEC Spine Group.5, 6
No public evidence identified that Alphatec issued a new statement after the 2021 acquisition endorsing or politically promoting the historical Israeli transaction.
Comparative public posture.
The reviewed 2024 annual filing, 2026 quarterly filing, and 2026 corporate disclosures document the company’s commercial and financial activities but do not establish a comparable programme of public corporate advocacy concerning Ukraine, Russia, or other geopolitical conflicts.7, 8
No public evidence identified sufficient to establish a documented difference between Alphatec’s responses to Palestinian civilian harm and its public responses to other conflicts.
Regional market framing.
Alphatec’s 2024 Form 10-K describes product marketing in the United States and international markets through independent sales agents and direct sales representatives; the filing identifies Alphatec Spine, SafeOp, and EOS imaging as wholly owned subsidiaries.7
Its June 2026 quarterly disclosure provides consolidated corporate and financial information without identifying an Israel-specific political partnership in the reviewed material.8
EOS imaging’s April 2017 [pre-2020] Israel announcement described the sale as an extension of its international installed base, identifying Tel Aviv Sourasky Medical Center as a clinical reference institution.5
The present EOS corporate profile identifies the company as part of the ATEC Spine Group and describes an international medical-imaging business whose systems are available in more than 40 countries.6
No public evidence identified of corporate communications describing Israeli operations as a strategic geopolitical undertaking.
Operations in Occupied or Contested Territories
Territorial presence.
Alphatec’s 2024 Form 10-K identifies a global medical-device business with international sales channels, but its cited international business disclosures do not establish sales, subsidiaries, facilities, dealers, or service contracts at specific addresses in the occupied Palestinian territory.7
Historical EOS imaging activity in Israel.
On 5 April 2017 [pre-2020], EOS imaging issued an official announcement titled “EOS imaging Announces First Sale of EOS System in Israel,” identifying Tel Aviv Sourasky Medical Center as its first customer in Israel.5
The announcement stated that the EOS platform was expected to be installed during April 2017 at Dana-Dwek Hospital, part of Tel Aviv Sourasky Medical Center.5
The same announcement identified the sale as expanding the EOS platform’s international presence to 33 countries.5
The announcement quoted then-CEO Marie Meynadier describing the customer as a reference site for orthopedic care and referring to Israeli patients’ prospective access to the company’s medical-imaging technology.5
The April 2017 announcement establishes a historical medical-equipment sale in Tel Aviv before Alphatec acquired EOS imaging; the document does not establish an installation within an Israeli settlement.5
The original announcement remains publicly accessible through an EOS imaging corporate-domain URL as of the October 2026 research session.5
Post-acquisition attribution and public availability.
In May 2021, Alphatec announced that its tender-offer process had secured approximately 89% of EOS imaging’s common shares and voting rights at the relevant transaction stage.9
EOS imaging’s current news archive identifies a 7 June 2021 announcement titled “EOS imaging joins the ATEC family!”10
By September 2026, Alphatec’s corporate disclosures identified EOS imaging S.A.S., Alphatec Spine, Inc., and SafeOp Surgical, Inc. as wholly owned subsidiaries.11
The present EOS corporate website independently identifies EOS imaging as part of the ATEC Spine Group and includes a navigation link to the ATEC website.6
The original April 2017 announcement therefore remains publicly retrievable from the acquired EOS business’s website more than five years after the acquisition.5, 6, 10
The evidence establishes public accessibility of the historical announcement in October 2026 and its original April 2017 publication date; it does not document uninterrupted availability throughout every intervening year.5
EOS imaging’s public product-documentation page contains medical-device documentation dated September and October 2026, establishing that its public website continues to display current product materials.12
The original 2017 announcement and the dated 2026 product materials are publicly accessible on the same corporate domain, but the retrieved pages do not establish that the historical Israel announcement was republished as a new 2026 announcement.5, 12
The available sources establish public access to the original announcement but do not provide verified audience statistics, traffic volumes, or a documented contemporary promotional campaign directed at that announcement.5, 6, 10
No public evidence identified of a current corporate navigation link expressly promoting the historical Israeli sale.
No public evidence identified establishing that Alphatec renewed the original Israeli customer relationship after acquiring EOS imaging.
No public evidence identified of a post-2021 Israeli distribution agreement, a new sale arising from that historical announcement, or continued equipment servicing attributable to the original transaction.
No public evidence identified establishing the current operating status of the original Dana-Dwek installation.
No public evidence identified of a formal withdrawal or retraction of the April 2017 EOS announcement.
Other EOS imaging operations.
Alphatec’s July 2024 launch of EOS Insight identified OrthoIndy Hospital as the site of its initial customer implementation and described the product as an artificial-intelligence-supported spinal imaging and planning platform.13
The initial implementation disclosed in that July 2024 announcement was a clinical installation in the United States.13
No public evidence identified of Alphatec-controlled equipment, services, reseller branches, facilities, or subsidiaries operating specifically within Israeli settlements in the West Bank, East Jerusalem, or the occupied Syrian Golan.
Israeli government and military procurement.
In April 2025, Alphatec announced the commercial launch of PTP Corpectomy, identifying applications in complex thoracolumbar surgery and describing its commercial purpose in clinical terms.14
In September 2026, the company identified EOS imaging, EOS Insight, Valence navigation and robotics, SafeOp neuromonitoring, and patient-specific surgical solutions as components of its medical technology portfolio.11
The EOS imaging announcement of April 2017 identifies a civilian medical-centre customer and an orthopedic imaging platform.5
No public evidence identified of an Israeli Ministry of Defense contract, IDF procurement agreement, military equipment deployment, or settlement-related public tender naming Alphatec Holdings or its verified subsidiaries.
No public evidence identified linking the historical EOS sale to Israeli military procurement or settlement infrastructure.
Legal and regulatory scrutiny.
Alphatec’s June 2026 quarterly filing discusses litigation contingencies arising from ordinary business activities; this disclosure does not establish proceedings concerning Israeli settlements or Israel-Palestine-related corporate conduct.8
No public evidence identified of a verified Alphatec Holdings listing in the searched OHCHR settlement-business records, a target-specific finding in the searched A/HRC/59/23 materials, or a confirmed settlement-related regulatory action against the company.
No public evidence identified of a relevant OECD National Contact Point complaint or litigation alleging Alphatec’s contribution to settlement activity.
Civil-society investigations and boycott campaigns.
No public evidence identified of a target-specific investigation concerning Israeli settlements by Who Profits, AFSC Investigate, Amnesty International, Human Rights Watch, B’Tselem, Al-Haq, or SOMO in the material retrieved for this audit.
No public evidence identified of an organised Israel-Palestine-related boycott, divestment, or sanctions campaign naming Alphatec Holdings or its verified subsidiaries.
No public evidence identified of a corresponding corporate response to such a campaign.
Internal Governance, Content & Retail Policies
Employee relations.
The company’s April 2026 proxy statement describes executive compensation, board oversight, governance arrangements, and employee equity incentives.15
The June 2026 annual-meeting disclosure confirms shareholder approval of the company’s 2026 Equity Incentive Plan and Employee Stock Purchase Plan.16
No public evidence identified of employee disciplinary proceedings, dismissals, labour disputes, or litigation specifically concerning expression of support for Palestine or Israel.
No public evidence identified of an Alphatec corporate policy restricting Palestinian symbols, Palestine-related employee speech, or participation in peaceful demonstrations.
No public evidence identified of litigation against trade unions for Palestine-related advocacy.
Reservist and military-leave policies.
No public evidence identified of an Israel-specific employee reservist-pay subsidy, salary-continuation arrangement, or supplementary military-leave programme operated by Alphatec or its verified subsidiaries.
Platform and editorial policies.
Alphatec’s July 2024 EOS Insight announcement describes the use of imaging and artificial intelligence for surgical planning, while its September 2026 corporate announcement describes clinical analytics and related medical technologies.13, 11
These documented systems are presented as medical technology platforms, with no disclosed consumer social-media content-moderation function in the cited product descriptions.13, 11
EOS imaging’s current corporate website likewise describes medical imaging, surgical planning, and orthopedic-care applications.6
No public evidence identified of Alphatec suppressing Palestinian digital content, restricting Gaza-related publications, or operating an Israel-Palestine-related editorial censorship programme.
No public evidence identified of an applicable mapping or cartographic policy concerning recognition or labelling of Palestinian territory.
Retail and supply-chain policies.
The company’s 2025 commercial announcement describes PTP Corpectomy as a clinical surgical system, while its 2026 announcements identify imaging, planning, neuromonitoring, and surgical technologies as principal product categories.14, 11
No public evidence identified of settlement-origin product labelling controversies, settlement sourcing decisions, or consumer retail categorisation policies involving Alphatec.
No public evidence identified of regulatory proceedings concerning the origin labelling of Alphatec medical devices in relation to Israeli settlements.
Charitable matching and employee giving.
No public evidence identified of an Alphatec charitable matching programme specifically permitting or excluding donations to the IDF, FIDF, JNF/KKL, settlement organisations, or Israeli military-support charities.
No public evidence identified of changes to such a programme following October 2023.
Brand Heritage & State Partnerships
Corporate heritage and commercial positioning.
Alphatec’s official investor-relations profile identifies its stated commercial vision as advancing spinal surgery through clinical innovation and the Alpha InformatiX technology ecosystem.2
The March 2018 [pre-2020] acquisition announcement described SafeOp Surgical as a medical neuromonitoring technology business and reported an approximately $50 million associated financing transaction.17
That historical acquisition remains relevant to the current corporate group because September 2026 disclosures continue to identify SafeOp Surgical as a wholly owned Alphatec subsidiary.11
The March 2018 [pre-2020] transaction announcement identified Luiz Pimenta as an incoming Chief Medical Officer and named clinical and medical-device personnel connected with the SafeOp acquisition.17
The 2018 clinical and technological relationship is documented historically, while the continued presence of those particular individuals in their original roles is not established by that announcement.17
EOS imaging’s historical Israeli commercial publicity.
The April 2017 [pre-2020] EOS imaging announcement publicly identified Tel Aviv Sourasky Medical Center as the company’s first Israeli customer and described the transaction in terms of medical innovation and international market expansion.5
The historical announcement is still publicly retrievable from the EOS imaging domain, and the current website identifies EOS as belonging to the ATEC Spine Group.5, 6
The EOS website separately identifies the June 2021 announcement concerning EOS joining the ATEC family.10
No public evidence identified of Alphatec issuing a new post-acquisition marketing campaign specifically promoting the 2017 Israeli installation.
Military heritage.
No public evidence identified of Alphatec promoting Israeli military heritage, Israeli intelligence-service origins, IDF service, or Israeli defence-sector sponsorship as part of its corporate brand.
Academic, government, and institutional partnerships.
The July 2024 EOS Insight announcement names OrthoIndy Hospital and surgeons David G. Schwartz and Craig McMains in connection with its first disclosed customer implementation.13
The historical April 2017 EOS announcement identifies Tel Aviv Sourasky Medical Center as a civilian medical and research institution purchasing imaging equipment.5
No public evidence identified of a formal non-commercial Alphatec partnership with an Israeli military academy, Israeli state-security institution, or settlement-based academic organisation.
No public evidence identified of sponsorship of an Israeli government public-relations campaign or settlement-related cultural programme.
State honours and official endorsements.
No public evidence identified of Alphatec accepting an Israeli state honour or hosting an Israeli government official in a documented geopolitical advocacy capacity.
Lobbying, Advocacy, Financing & Logistics
Corporate lobbying and political advocacy.
The company’s April 2026 definitive proxy statement identifies its seven director nominees and describes committee responsibilities relating to governance, compensation, and financial oversight.15
No public evidence identified establishing that Alphatec Holdings funded lobbying concerning Israeli territorial policy, anti-BDS legislation, United States military assistance to Israel, or sanctions concerning Palestinian territory.
No public evidence identified of a company-funded political action committee contribution specifically supporting legislation on Israel-Palestine.
No public evidence identified of an Alphatec corporate membership or leadership role in AIPAC, Conservative Friends of Israel, or another named Israel-related geopolitical pressure organisation.
Corporate financing and donations.
Alphatec’s May 2026 Form 8-K records a credit agreement including a $175 million term-loan facility and a $125 million revolving credit facility, with JPMorgan Chase Bank, N.A. acting as administrative agent.18
The disclosed terms establish a commercial corporate-financing relationship; the cited agreement disclosure does not identify a transaction financing Israeli military activity or settlement infrastructure.18
No public evidence identified of corporate donations or sponsorships by Alphatec to the IDF, Friends of the Israel Defense Forces, JNF/KKL, Israeli reservist organisations, Regavim, Im Tirtzu, or settlement-support organisations.
No public evidence identified of corporate funding of Israeli military-welfare organisations or military-related charity appeals following October 2023.
Crisis asset mobilisation.
In September 2026, Alphatec described ongoing commercial development across imaging, surgical planning, robotics, neuromonitoring, and clinical analytics.11
EOS imaging’s original April 2017 Israeli transaction concerned a clinical orthopedic imaging platform, as described in its contemporaneous corporate announcement.5
No public evidence identified that Alphatec resources were provided free of charge, donated, or specifically mobilised for Israeli military operations, wartime government logistics, or organisations materially supporting settlement activity.
No public evidence identified of an Alphatec announcement offering military logistics, transportation, computing resources, medical equipment donations, or specialised services to Israeli armed forces following October 2023.
Conduct after July and November 2024.
The company continued commercial activity following 19 July 2024, including the July 2024 EOS Insight launch, the April 2025 PTP Corpectomy launch, and its September 2026 technology leadership appointment.13, 14, 11
Those dated announcements describe commercial medical-device activity rather than Israel-Palestine-specific political advocacy or military financing.13, 14, 11
The EOS imaging corporate website continues to identify EOS as part of the ATEC Spine Group in October 2026 and contains product documentation dated September and October 2026.6, 12
The April 2017 Israeli sale announcement also remains publicly retrievable on the EOS imaging domain in October 2026.5
The original announcement predates both the ICJ advisory opinion of 19 July 2024 and the ICC arrest warrants issued in November 2024; the identified post-2024 fact is continued public availability of historical corporate material.5
No public evidence identified of relevant Alphatec political financing or military-support conduct commencing or escalating after 19 July 2024 or after November 2024.
No public evidence identified of a post-2024 renewal of the historical EOS Israeli customer relationship.
Settlement-related sponsorship.
No public evidence identified of Alphatec sponsoring settlement events, donating to settlement entities, or issuing public statements politically endorsing the settlement enterprise.
Corporate Structure & Primary Mission
Incorporation and corporate identity.
SEC records identify Alphatec Holdings, Inc. as a Delaware corporation with principal executive offices in Carlsbad, California and securities reporting under CIK 0001350653.1
The company’s February 2026 annual filing concerns the financial year ending 31 December 2025 and identifies Alphatec Holdings as the registrant.19
The company’s 2024 Form 10-K identifies Alphatec Spine, SafeOp Surgical, and EOS imaging as wholly owned subsidiaries conducting medical technology activities.7
The company’s September 2026 corporate announcement confirms the continuing identification of those three businesses as wholly owned subsidiaries.11
Acquisition history.
Alphatec acquired SafeOp Surgical in March 2018 [pre-2020] as part of a transaction involving medical neuromonitoring technology and approximately $50 million in associated equity financing.17
Alphatec announced substantial progress in acquiring EOS imaging in May 2021, reporting approximately 89% ownership of its common shares and voting rights at the specified completion stage.9
The EOS imaging corporate news archive records a June 7, 2021 announcement concerning EOS joining the ATEC family.10
The current EOS website confirms the post-acquisition group relationship by explicitly identifying EOS imaging as part of the ATEC Spine Group.6
The company subsequently integrated EOS imaging technologies into its EOS Insight surgical planning platform, commercially launched in July 2024.13
Historical corporate activity inherited through acquisition.
EOS imaging’s original April 2017 [pre-2020] announcement predates Alphatec’s acquisition and documents a commercial sale to Tel Aviv Sourasky Medical Center.5
The historical transaction is attributable to EOS imaging at the time of the announcement, while Alphatec’s subsequent ownership of EOS is established by its 2021 acquisition disclosures and 2026 corporate identification.5, 9, 11
The continued public availability of the historical announcement establishes its accessibility within the acquired company’s web presence; the original publication date remains April 2017.5, 6
No public evidence identified establishing that Alphatec itself negotiated, financed, renewed, or independently promoted the original transaction after acquiring EOS.
Corporate mission.
The company’s official investor profile characterises the enterprise as a developer of technologies and clinical approaches intended to advance spinal surgery.2
The EOS corporate profile describes its activities as medical imaging, orthopedic-care workflow development, and surgical planning.6
No public evidence identified of a corporate charter provision establishing advancement of Israeli state policy, Israeli military capacity, settlement development, or geopolitical advocacy as Alphatec’s primary corporate purpose.
State ownership and control.
The April 2026 proxy statement identifies shareholder interests and beneficial ownership associated with company directors and their investment vehicles, including Squadron Capital LLC and MOM, LLC.15
The reviewed ownership disclosures do not establish an Israeli state-held golden share or Israeli government voting-control arrangement.15
No public evidence identified of Israeli state ownership or a statutory mandate requiring Alphatec to advance Israeli geopolitical objectives.
Leadership-linked investment vehicles.
The company’s April 2026 proxy statement identifies 10,395,045 common shares and warrants covering 3,413,265 additional shares held by Squadron Capital LLC, and explains director David R. Pelizzon’s relationship with that entity.15
The same proxy statement identifies 250,000 Alphatec shares held by MOM, LLC and states that Patrick Miles is its manager.15
No public evidence identified connecting either investment vehicle to the financing of Israeli settlements or Israeli military-support organisations.
Current securities governance.
On June 10, 2026, Alphatec shareholders approved the company’s 2026 Equity Incentive Plan and Employee Stock Purchase Plan.16
An August 2026 SEC registration statement identifies Tyson E. Marshall as Alphatec’s General Counsel and Secretary in connection with the company’s employment inducement equity plan.20
The company’s June 2026 quarterly results disclosure describes a continuing commercial medical-device operation and reports approximately $214 million in second-quarter revenue.4
The company’s financial-results archive continues to provide access to its periodic financial disclosures.21
Executive & Leadership Footprint
Board and senior management.
The April 2026 proxy statement identified Patrick S. Miles, Mortimer Berkowitz III, Quentin Blackford, David Demski, Karen K. McGinnis, David R. Pelizzon, and Keith Valentine as the seven nominees for election to the company’s board of directors.15
The company’s official governance website identifies Patrick Miles as Chairman and Chief Executive Officer and describes his prior senior leadership roles at NuVasive.22
The April 2026 proxy statement identifies Mortimer Berkowitz III as lead director and describes committee memberships and directors’ backgrounds in finance, healthcare, medical devices, and corporate governance.15
The same proxy describes Quentin Blackford’s leadership at iRhythm Technologies and earlier executive responsibilities at DexCom and NuVasive.15
It also documents David Demski’s prior leadership and board involvement with Globus Medical and other medical technology businesses.15
Current EOS imaging leadership and group attribution.
EOS imaging’s current corporate website identifies Patrick Miles as Chairman and Chief Executive Officer and describes his Alphatec leadership tenure beginning in October 2017.6
The EOS corporate page also identifies Craig Hunsaker in People & Culture, Todd Koning in Finance, Scott Lish in Operations, Tyson Marshall in Legal, Dave Sponsel in Sales, Ali Shorooghi in Marketing, and Joseph Walland in Imaging Solutions.6
The page identifies EOS imaging as part of the ATEC Spine Group, establishing the present public corporate context for the acquired imaging business.6
No public evidence identified linking these executives’ current EOS responsibilities to Israel-Palestine political advocacy, settlement support, or Israeli military financing.
Executive changes during 2026.
On September 23, 2026, Alphatec appointed Thomas “Tommy” Carls as Executive Vice President, Data Intelligence and Strategy, reporting directly to Patrick Miles.11
The company stated that Carls would lead work concerning EOSedge, EOS Insight, analytics, and the wider InformatiX strategy.11
Governance and principal ownership.
The April 2026 proxy statement associates David Pelizzon with Squadron Capital LLC and Patrick Miles with MOM, LLC through disclosed beneficial-ownership arrangements.15
The company’s June 2026 shareholders’ meeting resulted in approval of its new employee and executive equity-related plans.16
Historical leadership relationships.
The March 2018 [pre-2020] SafeOp announcement identified Patrick Miles as Chief Executive Officer, Terry Rich as President and Chief Operating Officer, and Luiz Pimenta as Chief Medical Officer.17
Patrick Miles’ leadership role is confirmed as continuing in 2026 by the current corporate governance and September 2026 executive appointment disclosures.22, 11
The continuation of every other individual role from the March 2018 announcement is not established by that historical document.17
EOS imaging’s original April 2017 [pre-2020] announcement identified Marie Meynadier as its Chief Executive Officer at the time of the Israeli medical-equipment sale.5
That announcement predates the 2021 Alphatec acquisition and does not establish Meynadier’s subsequent executive responsibilities within the acquired company.5, 9
Personal philanthropy and political financing.
No public evidence identified of a verified personal donation by Patrick Miles or the other named directors and senior executives to the IDF, FIDF, JNF/KKL, settlement organisations, Israeli military-welfare programmes, or identified Israel-related geopolitical lobbying bodies.
No public evidence identified of a principal-controlled foundation making documented grants to such organisations.
No public evidence identified of a verified family-office donation financing Israeli military operations or settlement activity.
Personal advocacy and public statements.
The April 2025 PTP Corpectomy announcement quotes Patrick Miles discussing clinical technologies and surgical outcomes.14
The September 2026 executive appointment announcement quotes Miles discussing surgical technology, analytics, and the company’s innovation strategy.11
The April 2017 [pre-2020] EOS imaging announcement quotes then-CEO Marie Meynadier discussing access to medical-imaging technology and the expansion of the company’s international installed base.5
No public evidence identified of a verified statement by the named Alphatec directors or executives endorsing Israeli military action, endorsing settlement expansion, advocating forced displacement, or participating in an anti-BDS campaign in a capacity attributable to Alphatec.
Board memberships and political affiliations.
The company’s 2026 proxy statement documents various commercial and healthcare-industry positions held by its directors.15
No public evidence identified of an Alphatec director holding a verified board or leadership position in a named organisation whose disclosed role establishes Israel-Palestine-related political lobbying, settlement financing, or Israeli military-support fundraising.
Executive-linked military or defence investments.
No public evidence identified of a verified controlling investment by a named Alphatec principal in an Israeli military, defence, intelligence, or surveillance company.
No public evidence identified of an Alphatec executive or director undertaking fundraising for Israeli military units or settlement-support organisations after October 2023.
Footnotes
-
U.S. Securities and Exchange Commission, Alphatec Holdings, Inc., EDGAR company record, accessed October 2026. https://www.sec.gov/edgar/browse/?CIK=0001350653 ↩ ↩2
-
Alphatec Holdings, Inc., Investor Relations, Corporate Profile, accessed October 2026. https://investors.alphatecspine.com/overview/ ↩ ↩2 ↩3
-
Alphatec Holdings, Inc., “ATEC Announces Select Preliminary Financial Results for 2025 and Provides 2026 Outlook,” January 12, 2026. https://investors.alphatecspine.com/press-releases/news-details/2026/ATEC-Announces-Select-Preliminary-Financial-Results-for-2025-and-Provides-2026-Outlook/default.aspx ↩
-
Alphatec Holdings, Inc., “ATEC Reports Second Quarter Financial Results,” August 4, 2026. https://investors.alphatecspine.com/press-releases/news-details/2026/ATEC-Reports-Second-Quarter-Financial-Results/default.aspx ↩ ↩2
-
EOS imaging, “EOS imaging Announces First Sale of EOS System in Israel,” original corporate press release, April 5, 2017; publicly retrieved October 26, 2026. https://www.eos-imaging.com/wp-content/uploads/2017/04/170405_Israel-First-Sale_US.pdf.pdf ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22 ↩23 ↩24 ↩25 ↩26
-
EOS imaging, “About EOS imaging,” current corporate profile identifying EOS imaging as part of the ATEC Spine Group, accessed October 26, 2026. https://www.eos-imaging.com/about-eos ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14
-
Alphatec Holdings, Inc., Form 10-K, fiscal year ended December 31, 2024, SEC filing, February 2025. https://www.sec.gov/Archives/edgar/data/1350653/000095017025027916/atec-20241231.htm ↩ ↩2 ↩3 ↩4
-
Alphatec Holdings, Inc., Form 10-Q, quarterly period ended June 30, 2026, filed August 2026. https://www.sec.gov/Archives/edgar/data/1350653/000119312526333051/atec-20260630.htm ↩ ↩2 ↩3
-
Alphatec Holdings, Inc. and EOS imaging, “Strong Success of the Tender Offer Initiated by Alphatec Holdings for Common Shares and OCEANEs of EOS IMAGING,” May 12, 2021. https://investors.alphatecspine.com/press-releases/news-details/2021/Strong-Success-of-the-Tender-Offer-Initiated-by-Alphatec-Holdings - for-Common-Shares-and-OCEANEs-of-EOS-IMAGING/default.aspx ↩ ↩2 ↩3 ↩4
-
EOS imaging, “News,” corporate news archive identifying the June 7, 2021 announcement “EOS imaging joins the ATEC family!”, accessed October 26, 2026. https://www.eos-imaging.com/news ↩ ↩2 ↩3 ↩4 ↩5
-
Alphatec Holdings, Inc., “ATEC Appoints Tommy Carls Executive Vice President, Data Intelligence and Strategy,” September 23, 2026. https://investors.alphatecspine.com/press-releases/news-details/2026/ATEC-Appoints-Tommy-Carls-Executive-Vice-President-Data-Intelligence-and-Strategy/default.aspx ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15
-
EOS imaging, “Product documentation,” corporate documentation page containing September and October 2026 product materials, accessed October 26, 2026. https://www.eos-imaging.com/product-documentation ↩ ↩2 ↩3
-
Alphatec Holdings, Inc., “ATEC Launches EOS Insight, an End-To-End Spine Surgery Platform Powered by EOS Imaging and AI,” July 24, 2024. https://investors.alphatecspine.com/press-releases/news-details/2024/ATEC-Launches-EOS-InsightTM-an-End-To-End-Spine-Surgery-Platform-Powered-by-EOS-Imaging-and-AI/default.aspx ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8
-
Alphatec Holdings, Inc., “ATEC Launches PTP Corpectomy, The Next Evolution of Lateral Approach Surgery,” April 21, 2025. https://investors.alphatecspine.com/press-releases/news-details/2025/ATEC-Launches-PTP-Corpectomy-The-Next-Evolution-of-Lateral-Approach-Surgery/default.aspx ↩ ↩2 ↩3 ↩4 ↩5
-
Alphatec Holdings, Inc., Definitive Proxy Statement, Schedule 14A, filed April 29, 2026. https://www.sec.gov/Archives/edgar/data/1350653/000119312526191867/atec-20260429.htm ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12
-
Alphatec Holdings, Inc., Form 8-K, results of June 10, 2026 annual meeting and approval of equity incentive and employee stock purchase plans. https://www.sec.gov/Archives/edgar/data/1350653/000119312526267552/atec-20260610.htm ↩ ↩2 ↩3
-
Alphatec Holdings, Inc., “Alphatec Spine Disrupts Market with Acquisition of SafeOp Surgical, ~$50M Equity Financing, and Strategic Leadership Appointments,” March 8, 2018. https://investors.alphatecspine.com/press-releases/news-details/2018/Alphatec-Spine-Disrupts-Market-with-Acquisition-of-SafeOp-Surgical-50M-Equity-Financing-and-Strategic-Leadership-Appointments/default.aspx ↩ ↩2 ↩3 ↩4 ↩5 ↩6
-
Alphatec Holdings, Inc., Form 8-K, May 1, 2026 senior secured credit agreement, filed May 2026. https://www.sec.gov/Archives/edgar/data/1350653/000119312526206530/atec-20260501.htm ↩ ↩2
-
U.S. Securities and Exchange Commission, Alphatec Holdings, Inc., Form 10-K filing details, accession 0001193125-26-067393, February 24, 2026. https://www.sec.gov/Archives/edgar/data/1350653/000119312526067393/0001193125-26-067393-index.htm ↩
-
Alphatec Holdings, Inc., Form S-8 registration statement, August 4, 2026. https://www.sec.gov/Archives/edgar/data/1350653/000119312526332954/atec-20260804.htm ↩
-
Alphatec Holdings, Inc., Financial Results and Quarterly Reports Archive, accessed October 2026. https://investors.alphatecspine.com/financials/financial-results/default.aspx ↩
-
Alphatec Holdings, Inc., Governance - Board of Directors, accessed October 2026. https://investors.alphatecspine.com/governance/board-of-directors/default.aspx ↩ ↩2